Cellectis S.A. (0WA2.L)

2,6500 -0,0680 (-2,50%) Alla chiusura: 05:40PM BST

Cellectis S.A.

8, rue de la Croix Jarry
Paris 75013
France
33 1 81 69 16 00
https://www.cellectis.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 231

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Andre Choulika Ph.D.	Co-Founder, CEO & Director	695,4k	N/D	1965
Dr. David j. d. Sourdive Ph.D.	Deputy CEO, Executive VP of CMC & Manufacturing and Director	494,36k	N/D	1967
Dr. Bing C. Wang M.B.A., Ph.D.	Chief Financial Officer	N/D	N/D	1977
Valerie Cros	Principal Financial Officer & Principal Accounting Officer	N/D	N/D	N/D
Mr. Jean Charles Epinat	Chief Technological Officer	N/D	N/D	N/D
Dr. Philippe Duchateau Ph.D.	Chief Scientific Officer	N/D	N/D	1963
Mr. Stephan Reynier M.Sc.	Chief Regulatory & Pharmaceutical Compliance Officer	N/D	N/D	1969
Ms. Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors	N/D	N/D	1982
Pascalyne Wilson	Director of Communications	N/D	N/D	N/D
Ms. Kyung Nam-Wortman	Executive VP & Chief Human Resources Officer	N/D	N/D	1970

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Governance aziendale

L'ISS Governance QualityScore di Cellectis S.A. al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 10; diritti degli azionisti: 9; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.